Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

DIDA-Seq Custom Capture cfDNA Library Preparation v1

View through CrossRef
Dual Index Degenerate Adaptor Sequencing, or DIDA-Seq, an ultra-sensitive cell-free DNA sequencing approach for the detection and quantification of circulating tumor DNA in peripheral blood plasma at fractions below the background error-rate of traditional next-generation sequencing (NGS). DIDA-Seq combines unique molecular identifiers (UMIs) and patient-specific custom capture panels to routinely detect ctDNA with mutation allele frequencies at or below 0.02% (or 1 tumor derived DNA fragment in 5k normal fragments at a given genomic locus) with error-rates below 1 base in 10kb-50kb (Butler et al 2019, doi:10.1101/mcs.a003772; Boniface et al 2021, doi:10.3390/diagnostics11010073). This protocol describes the preparation of DIDA-Seq libraries using cell-free DNA, custom DIDA-seq library adaptors and blocking oligonucleotides, and custom hybridization capture panels. It uses reagents developed and manufactured by Roche, LTD and Integrated DNA Technologies, Inc with minimally modified versions of their methods.
Title: DIDA-Seq Custom Capture cfDNA Library Preparation v1
Description:
Dual Index Degenerate Adaptor Sequencing, or DIDA-Seq, an ultra-sensitive cell-free DNA sequencing approach for the detection and quantification of circulating tumor DNA in peripheral blood plasma at fractions below the background error-rate of traditional next-generation sequencing (NGS).
DIDA-Seq combines unique molecular identifiers (UMIs) and patient-specific custom capture panels to routinely detect ctDNA with mutation allele frequencies at or below 0.
02% (or 1 tumor derived DNA fragment in 5k normal fragments at a given genomic locus) with error-rates below 1 base in 10kb-50kb (Butler et al 2019, doi:10.
1101/mcs.
a003772; Boniface et al 2021, doi:10.
3390/diagnostics11010073).
This protocol describes the preparation of DIDA-Seq libraries using cell-free DNA, custom DIDA-seq library adaptors and blocking oligonucleotides, and custom hybridization capture panels.
It uses reagents developed and manufactured by Roche, LTD and Integrated DNA Technologies, Inc with minimally modified versions of their methods.

Related Results

Abstract 1694: Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells
Abstract 1694: Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells
Abstract Introduction: Detection of circulating free DNA (cfDNA) is a promising tool to monitor and predict tumor progression and treatment efficacy. Our group has s...
Circulating Cell-free Human Papillomavirus DNA as a Tumor Marker in Recurrent or Metastatic Cervical Cancer: A Pilot Study
Circulating Cell-free Human Papillomavirus DNA as a Tumor Marker in Recurrent or Metastatic Cervical Cancer: A Pilot Study
PURPOSE: Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularly cervic...
Cell-Free DNA Promotes Inflammation in Patients With Oral Lichen Planus via the STING Pathway
Cell-Free DNA Promotes Inflammation in Patients With Oral Lichen Planus via the STING Pathway
BackgroundDamaged and dead cells release cell-free DNA (cfDNA) that activates cyclic GMP–AMP (cGAMP) synthase (cGAS), which leads to the activation of stimulator of interferon gene...
Abstract 4553: Evaluation of cfDNA release profiles in colorectal cancer patients during surgery
Abstract 4553: Evaluation of cfDNA release profiles in colorectal cancer patients during surgery
Abstract Surgical intervention is one of the most employed treatments for colorectal cancer, especially in patients with localized disease. However, the dynamics of ...

Back to Top